{"ticker": {"uuid": "01c360fc-b43d-4e06-9aad-9aa6da32e315", "symbol": "ATOS", "name": "Atossa Genetics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Atossa Therapeutics Inc (ATOS) has an earnings forecast score of 8.00, placing it 170th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.50 for ATOS, with a \"Buy\" recommendation based on the ratings of two analysts. The company's p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atos/earnings", "source_name": "TradingKey", "published_at": "2026-07-13T02:10:51", "published_display": "13 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "The article displays the \"Price to sales forward\" financial metric for Atossa Therapeutics, Inc. (Symbol: YAG) on the Dusseldorf Stock Exchange. It indicates no current trades as the market is closed. The content primarily provides navigation and informational links related to Tr", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T00:40:11", "published_display": "13 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "This article focuses on the enterprise value to revenue forward for Atossa Therapeutics, Inc. (DUS:YAG). It provides a financial overview of the company as traded on the Dusseldorf Stock Exchange. The content appears to be a stub or a section of a larger financial data presentati", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T18:10:29", "published_display": "12 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to cash flow ratio of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "This page provides financial data, specifically the price to cash flow ratio, for Atossa Therapeutics, Inc. (YAG) on the Dusseldorf Stock Exchange. It notes that the market is currently closed with no trades. The content primarily outlines the financial overview and related servi", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/price-cash-flow/", "source_name": "TradingView", "published_at": "2026-07-09T12:10:39", "published_display": "09 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12", "summary": "Rodman & Renshaw has initiated coverage of Atossa Therapeutics (ATOS.US) with a Buy rating. The firm also announced a target price of $12 for the stock. This news indicates a positive outlook from Rodman & Renshaw regarding the future performance of Atossa Therapeutics.", "url": "https://www.moomoo.com/news/post/72625996/rodman-renshaw-initiates-atossa-therapeutics-atosus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-08T10:11:06", "published_display": "08 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy", "summary": "Rodman & Renshaw has initiated coverage on Atossa Therapeutics (ATOS) with a Buy rating and a $12.00 price target. Despite a strong financial standing (9/10), the company faces challenges in profitability and growth, reflected in its GF Score\u2122 of 26/100. Investors are advised to ", "url": "https://www.gurufocus.com/news/8948009/atos-initiates-coverage-on-rodman-renshaw-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-07-07T18:11:32", "published_display": "07 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com", "summary": "Rodman & Renshaw has initiated coverage on Atossa Genetics Inc. (NASDAQ:ATOS) with a buy rating and a $12.00 price target. The firm highlighted Atossa's estrogen receptor modulator, which shows clinical activity in breast cancer treatment and has validated clinical results, along", "url": "https://za.investing.com/news/stock-market-news/rodman--renshaw-initiates-atossa-genetics-stock-with-buy-rating-93CH-4358519", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T14:11:32", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Atossa Genetics stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNl9UaVFKUEpWLXhkVS1pVmdpdVdYWVhPVnY2WGVKN181Y2V1dkRPNTBfekZDUWNvMlpCOV9QaHQ2N3JDYnBLbldqS1BKVUJPTUVpeXlaMHNpb2V5MktReXlNdjZxM3l6UXA0SXhEb09Gb1JhZlE3MnpsWklTSjU3dExZNHJhcEE3WWRQNkZBX3dOSEJjRGxXU211aVpWWGE5RHYySW51UEpzVndpcFZWQ0lEY3dYTzVvbmh1Y01uUWo?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T12:38:29+00:00", "published_display": "07 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATOS - Atossa Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Atossa Therapeutics Inc.'s (ATOS) financial data and stock performance, with a specific focus on its short interest. Key metrics include market capitalization, price-to-book ratio, EPS growth, insider and institutional ownership, and v", "url": "https://finviz.com/stock?t=ATOS&ta=1&p=m&ty=si&b=2", "source_name": "Finviz", "published_at": "2026-07-07T00:11:32", "published_display": "07 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index", "summary": "Atossa Therapeutics, Inc. (NasdaqCM:ATOS) has been added to the Russell Microcap Value Benchmark Index. This inclusion follows its recent addition to the Russell 3000E Index, the Russell Microcap Index, and the Russell 3000E Growth Benchmark. The company is a clinical-stage bioph", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:16", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index", "summary": "Atossa Therapeutics, Inc. (NasdaqCM: ATOS) has been added to the Russell Microcap Index, as announced on June 29, 2026. This inclusion is significant for the clinical-stage biopharmaceutical company, which focuses on developing treatments for women\u2019s breast cancer and other breas", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-microcap-index-ce7f5fdeda81f02d", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:09:57", "published_display": "29 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atossa Therapeutics, Inc. \u2013 NASDAQ:ATOS", "summary": "This article provides financial information for Atossa Therapeutics, Inc. (NASDAQ: ATOS), specifically its \"Price to book forward\" metric. The content emphasizes that the market was closed at the time of publication, and no trades were made. It also lists various data sources and", "url": "https://www.tradingview.com/symbols/NASDAQ-ATOS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:11:33", "published_display": "29 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark", "summary": "Atossa Therapeutics, Inc. (ATOS) has been included in the Russell 3000E Growth Benchmark. This addition highlights the clinical-stage biopharmaceutical company's progress in developing medicines for unmet medical needs in oncology, particularly focusing on breast cancer with its ", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f527", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:11:33", "published_display": "29 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This page provides financial information for Atossa Therapeutics, Inc. (MUN:YAG), specifically focusing on its forward price-to-sales ratio. It indicates that the market for this stock was closed with no trades recorded at the time of viewing. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:09", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This article provides financial information for Atossa Therapeutics, Inc. (MUN:YAG) listed on the Munich Stock Exchange, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's financial data and is presented within the TradingView plat", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:11:33", "published_display": "26 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This article displays the price to book forward metric for Atossa Therapeutics, Inc. (MUN:YAG) on the Munich Stock Exchange. It notes the market is currently closed with no trades. The information is presented within the TradingView platform context.", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:24", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic?", "summary": "Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biopharmaceutical company, is expected by analysts to reach profitability in 2028, after incurring a loss of US$38m in the latest trailing-twelve-month period. This breakeven projection relies on a very high average annual growt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atos/atossa-therapeutics/news/atossa-therapeutics-inc-nasdaqatos-are-analysts-optimistic", "source_name": "Simply Wall Street", "published_at": "2026-06-25T10:39:59", "published_display": "25 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com", "summary": "Atossa Therapeutics has announced a registered direct offering to institutional investors, aiming to raise approximately $4.5 million in gross proceeds. The offering involves the sale of common stock and warrants, with potential for an additional $12 million if warrants are fully", "url": "https://ng.investing.com/news/stock-market-news/atossa-therapeutics-raises-45m-in-registered-direct-offering-93CH-2553830", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T16:11:01", "published_display": "19 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds", "summary": "Atossa Therapeutics announced the closing of a registered direct offering, generating approximately $4.5 million in gross proceeds upfront, with the potential for an additional $12 million from warrant exercises. The offering involved shares of common stock and Series A and Serie", "url": "https://www.biospace.com/press-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds", "source_name": "BioSpace", "published_at": "2026-06-14T13:48:50", "published_display": "14 Jun 2026 13:48", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics closes $4.5M registered direct offering By Investing.com", "summary": "Atossa Therapeutics recently completed a registered direct offering, securing $4.5 million in gross proceeds. This financing involved the sale of common stock and warrants, which could bring in an additional $12 million if fully exercised. The company plans to use these funds for", "url": "https://ng.investing.com/news/stock-market-news/atossa-therapeutics-closes-45m-registered-direct-offering-93CH-2556863", "source_name": "Investing.com Nigeria", "published_at": "2026-06-13T01:39:03", "published_display": "13 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-drug developer Atossa raises $4.5M, eyes $12M more", "summary": "Atossa Therapeutics has closed a registered direct offering, securing approximately $4.5 million in gross proceeds from the sale of common shares and warrants. The offering also provides the potential for an additional $12 million if all Series Warrants are fully exercised. The c", "url": "https://www.stocktitan.net/news/ATOS/atossa-therapeutics-announces-closing-of-registered-direct-offering-6motup1g63u1.html", "source_name": "Stock Titan", "published_at": "2026-06-13T01:09:57", "published_display": "13 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics closes $4.5M registered direct offering", "summary": "Atossa Therapeutics, Inc. has successfully completed a registered direct offering, securing approximately $4.5 million in gross proceeds. The biopharmaceutical company sold common stock and warrants, which could bring in an additional $12 million if fully exercised. Atossa plans ", "url": "https://www.investing.com/news/company-news/atossa-therapeutics-closes-45m-registered-direct-offering-93CH-4740652", "source_name": "Investing.com", "published_at": "2026-06-12T22:09:57", "published_display": "12 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering", "summary": "Atossa Therapeutics has announced a registered direct offering with institutional investors, expected to generate $4.5 million upfront and potentially up to $16.5 million if warrants are fully exercised. The offering includes common stock and Series A and B warrants, with proceed", "url": "https://pulse2.com/atossa-therapeutics-announces-up-to-16-5-million-registered-direct-offering/", "source_name": "Pulse 2.0", "published_at": "2026-06-12T20:39:03", "published_display": "12 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal", "summary": "Atossa Therapeutics is conducting a registered direct offering to sell 1,363,637 shares of common stock, each combined with one Series A warrant and one Series B warrant, at an offering price of $3.30 per share, aiming for gross proceeds of $4,500,002.10 and estimated net proceed", "url": "https://www.stocktitan.net/sec-filings/ATOS/424b5-atossa-therapeutics-inc-prospectus-supplement-debt-securities-27b92621b700.html", "source_name": "Stock Titan", "published_at": "2026-06-12T13:09:57", "published_display": "12 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Launches $16.5 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atossa-therapeutics-launches-16-5-123940376.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:39:40+00:00", "published_display": "11 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics stock tumbles on $4.5M stock offering", "summary": "Atossa Therapeutics Inc. (NASDAQ: ATOS) shares fell 30% in premarket trading after announcing a registered direct offering expected to raise $4.5 million. The company entered into an agreement with institutional investors to sell 1,363,638 shares of common stock at $0.18 par valu", "url": "https://www.investing.com/news/stock-market-news/atossa-therapeutics-stock-tumbles-on-45m-stock-offering-93CH-4737416", "source_name": "Investing.com", "published_at": "2026-06-11T13:09:31", "published_display": "11 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics raises $4.5M in registered direct offering", "summary": "Atossa Therapeutics, Inc. announced a registered direct offering raising approximately $4.5 million in gross proceeds. The clinical-stage biopharmaceutical company is selling over 1.3 million shares and accompanying warrants, with potential for an additional $12 million if warran", "url": "https://www.investing.com/news/company-news/atossa-therapeutics-raises-45m-in-registered-direct-offering-93CH-4737315", "source_name": "Investing.com", "published_at": "2026-06-11T12:40:21", "published_display": "11 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRjNZMk51a1lKYjRHV1AycHdqR1I1SzdpeHpPckJxZWhSR1JvLXd6dWh6bjkwVHVRdUpCUE9qVzNwLXlaTFpVXy1UUHFMdTNiTkRXTlFLYkx3U1ZnTEdZejQyejNVY0hBb2Z1MThQX29XcUR6R25IajJNeFpXT0M5QUo3RnU3MlBsSFBGOUZlc19DaFQydGpVb2ZXMXpXTE1Zb2pIMFJzbnREcGtPNXVzM2R4eDcwNU96MTg1Q0hsb3BCQWpkZFQ1NzF4bzVMb0ZYUWh6R3FFeHFya0VzUDNjMkRiVWc2cjQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOd0gzU20xb1JicDl1OVV0dGY4VlY0ekJjYWkwSWVmVUNIMFFfQ0RwYkQ1OE1VS1ExeDNRNWxXRDJZUi1KMHRIeF90d1ZrSG4zYVFmbC1faXJsRFRMUkt1OHFsVUlYSzMzdHM4TDF0OXdYdmZDVU0zb2E0QkRaUWx0V0dqbWdEZUU3VmhjUlVjeVZzd0ZzTE9zbmw3UFItdng0Ul9leEp1STB4MVpPVDN3R2RB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment", "summary": "", "url": "https://finance.yahoo.com/video/atossa-therapeutics-highlights-endoxifen-progress-165144742.html", "source_name": "Proactive", "published_at": "2026-06-10T16:51:44+00:00", "published_display": "10 Jun 2026 16:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ceo-chat-steven-quay-md-090500232.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-01T09:05:00+00:00", "published_display": "01 Jun 2026 09:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxQbVFCZnVDcGQ4b2lmMVhKY2RTWUl6YjVDdjh2V3hiVE55UUkyNGVrUGRSNFZJbjdHSXdvSXRESG9BQ0o4LUVDX0FrQV9EUGJ2UWRXa0lGNGNsMXpzMlV6bnhsVHJlU1RMT0hSQ1V6elVzQ2p5VUQtdE91bmhFYVhlSzIybzRHUGVHNVVwMU56TlRaLUVtRk9wT2ZfY3VWc2ZXc2hVcFl5c0RIc1E0Wm0xUUtTMVJRamJXZWJZeU1CTFRtNjJKNElyb2FwQmEyQUhJRklVZU9jNEFodXYzRFhvdlNZUkhwdDliWTFpQmVScW01elhfRWo5VWpYaGU2WUJ6SWRsMWtUbzg0VmxqanVFVldVTWFIaV9WczZqRHpvYk5VZ0RD?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOQk9CNTZXSUw3V0VKUXFIcFlNblJKM3ROdGpHY0RYWmVrX0gtaGo5SS1YcnpxX1JnS2poU2JLTGc4TENHaTQ1S3hiUnQyVGRIVHJ2OVh3TGxobEpqSkR3S2RCRTU4YnhzZFMzcHNaam80Ymo4LXFGVTNaejl6ZlA0U0tDck1FaWppRVNHQ19DWFl0U3FUWkwxYWFVOTd1LWRObUNKWXRsQ3lxcnV5OXZBNU96eHBoRXRjUDhYMzAyODdmSnlPRE9kYnFDeFR6Zng4V2ZZb0lndHduRXJlaWp4OE5pc190VXdRZi1YRlJVQXIteUVydTd3akNrVUUzcW1ldWR3ZTRBUDZzV3hCRmljUE1WZmRrQ1NMRFRicmlCeVNrY2swX0E?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atossa-therapeutics-host-virtual-kol-123000263.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atossa Therapeutics (NASDAQ: ATOS) wins OK for potential reverse stock split", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQQm1VamtBcGhab0R6NElKWlE3Um0wRUdRbXZoMl9tWEVZYTlseExmX2NoWjd2Q2E1ZUtmYVBJdzhjeHhZNC11OHlFMlZPdW9OQ25fMGhhaThyVUpBekE2ZmdsT2NpQXJvM1JsbkFTSmhBYWtOSWdZeVB3ckhVWmRsQkdOcGdoQ1M1SkItMm5nR09YTktLYUxpdXFIal9JSm9zUWh6WTRlUzdqdC1xRlU1dHp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics stock surges after FDA rare disease designation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOHYwdnhzam52OXkwc0JZZGtKY1BtU0JoTEFTelNOM3VtMFNSUmxaNk5LaEE5VnBHSEl1LURUamQzc19fRWNSaUF1a3RhakhWd3liT3JFVEE5WWV1cE1HSThZWXBKZWNvSlo4T0doM1Z3S2JndVg3N0NJRjNSc19TUlJwS0hhdDZxV0pPRExGa2xGNTlSV0Y2LTZ0dTNUWHo0cVV5UjM3dGtZV0kySHg2cmQ3andSMWtuZl9qOXh0dGxwTE0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atossa Therapeutics reaches settlement in Endoxifen patent dispute", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPVXZDbFVGajdmN2x6N0xlVGh1UUlxb0VDenFVNUkwR3JnaW9tOEl4NjdtZ2I1anlZVlZVLS1GRnB6eTJNWnh5b2stSHBIMXNoSUllcjlUVVM0SnNkSjVkV1hUUzJpSXNXaG9wOW5MM05Wckttanpla0xUWUJJUkNhM0hlbWZVZnJ3ZnVPVGtMUG1DUHZZSDRPM1lIQWsxaF9VVUFEakFjdWpLQ21hZXpDQWtEMmlpTE9KWmZpVkdudw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTV8tclhnZ2RvcEdVN1dmM0JoN2w4R19UMHNJeWkteDlMenJXNzE2XzJreVpWa1l4Z2xjQ01RU2NiUmtZanRWSUZ2bGd1RDNFalVoQmFsaGhKankyQUZSRTZCVE9CRk5PM0tkbUotQm83UDBweW5iajF5QzA0TGduME5MVWpDcHhOQW5F?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9LTGNSLWZFVmhkVzBubkZQZE0tUWotTU9LWVFDdVJwSmMyeUd6MU5PV2ZCNF9YTElpS09yVGVLWEtQN0ZiZ2U3VThyWENXUFV2UEpKOU0xNXFVSHJHVFhBSlhqZGJnaHla?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:04:39+00:00", "published_display": "09 Jul 2025 17:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) Stock Forecast and Price Target 2026 $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFA5QUNLN0w1Ri16UTFCeHUyOVRaemRRVjBtcm9lUDgzcTF3ZjhhMm9BYjlkRGRna281UXRlTFBydEhPZngwQjVMSENtTmwxVVVManRSMDVwdDFHdnA0UkpoRGxzWmpwZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T16:27:16+00:00", "published_display": "11 May 2024 16:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Atossa Genetics (ATOS) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNUFFCcXNDcnJjc0J1VGU1aVcwV2VrQ1Nrdm1iR1NLSGNCZ09iQ09VTjVObU9MMWFuSWFOZUtXUjdqT3ZSbHVIYlF3RWhNWW5Jc2l2N2tfUW42MnZHZnB1cGFoSnZmSjd1bE5ySU1zTEpGVTlKb294WEgtZzRYZVFEWA?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-29T04:32:22+00:00", "published_display": "29 Apr 2020 04:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) Stock Price, News & Analysis $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBBQVJfZDJSZENtXzJYVG82c1JRbXl6UlJDLUhfNzY1UXQtUFJQNGZyelU5M0JNSlBGRjF4RF85aTlGdXFiY0k4eEVVbGxHNzJ3RFk4dExnMDJvZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-21T18:04:37+00:00", "published_display": "21 Aug 2016 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics Announces FDA Acceptance of Its", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQUHRDZ1FHaWkzcVBCdTlXczd6SWRlLTBsM09WLVljQzNXakk3T3Boa1BPMTY5LUZQVDg0Z0I3UnB3OFNudy03UllScG5oRTZ4blVoajZSWW1HZ2ZOenNLSjBxTXBrWTVWRjJPdWRLZGdiU0ZSMnFKekpDUUxlTmtCaXdpQ2xGYTcySWNnaWZIVmlIVHUzcktfcWl6Tmo1Y3hQNlI2SDRiZnNkOXU0V1pEcXg2N2V3UDVEZm4xa3hGbGR4NHdMT2p4Q2pTU1RyakQ5UC1WMS1jeVREQ1plcEhsVktIQWVXa0VkRjN2S2lvTmlOLWx2MUg3RTA3eGhEaDNmT0lMcTQ0RUNRTDJNVTJGSW5xOFktQkRFaVhEZVRqR3h4M2E2c3pNb0NMbTliSHdHVWZPeDNrTjIyV3MwU014YVU0cFZWRTJHaE0zUGZwVWthZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2015-09-21T07:00:00+00:00", "published_display": "21 Sep 2015 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZlNfR3J0aklRUWRWTUV6MjdJTU0wRTVJZlZUSTAxSVYxczNqQU9hU0c5UXBZS0NlWVJCdWNDY2ZWbTJHTjN6cGMxNnJLNVBhLWxha3VIcmYyeEdqOTZOQllXRTdMUHJ5OW5nQk1DYWxKV3FLSFRtV01lSk54ZG1nb2Q0VkVQMUtkOWZoOVVMTnhWODc5SXRFenZwWWFqczNrN2tMMVg1NFh6dGdEeXo3WTZGTTU4QVFEdGdiaXdJV0Q?oc=5", "source_name": "News-Medical", "published_at": "2013-02-22T08:00:00+00:00", "published_display": "22 Feb 2013 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Atossa Therapeutics Inc (ATOS) has an earnings forecast score of 8.00, placing it 170th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.50 for ATOS, with a \"Buy\" recommendation based on the ratings of two analysts. The company's p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-atos/earnings", "source_name": "TradingKey", "published_at": "2026-07-13T02:10:51", "published_display": "13 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "The article displays the \"Price to sales forward\" financial metric for Atossa Therapeutics, Inc. (Symbol: YAG) on the Dusseldorf Stock Exchange. It indicates no current trades as the market is closed. The content primarily provides navigation and informational links related to Tr", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T00:40:11", "published_display": "13 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "This article focuses on the enterprise value to revenue forward for Atossa Therapeutics, Inc. (DUS:YAG). It provides a financial overview of the company as traded on the Dusseldorf Stock Exchange. The content appears to be a stub or a section of a larger financial data presentati", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T18:10:29", "published_display": "12 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to cash flow ratio of Atossa Therapeutics, Inc. \u2013 DUS:YAG", "summary": "This page provides financial data, specifically the price to cash flow ratio, for Atossa Therapeutics, Inc. (YAG) on the Dusseldorf Stock Exchange. It notes that the market is currently closed with no trades. The content primarily outlines the financial overview and related servi", "url": "https://www.tradingview.com/symbols/DUS-YAG/financials-statistics-and-ratios/price-cash-flow/", "source_name": "TradingView", "published_at": "2026-07-09T12:10:39", "published_display": "09 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12", "summary": "Rodman & Renshaw has initiated coverage of Atossa Therapeutics (ATOS.US) with a Buy rating. The firm also announced a target price of $12 for the stock. This news indicates a positive outlook from Rodman & Renshaw regarding the future performance of Atossa Therapeutics.", "url": "https://www.moomoo.com/news/post/72625996/rodman-renshaw-initiates-atossa-therapeutics-atosus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-08T10:11:06", "published_display": "08 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATOS Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy", "summary": "Rodman & Renshaw has initiated coverage on Atossa Therapeutics (ATOS) with a Buy rating and a $12.00 price target. Despite a strong financial standing (9/10), the company faces challenges in profitability and growth, reflected in its GF Score\u2122 of 26/100. Investors are advised to ", "url": "https://www.gurufocus.com/news/8948009/atos-initiates-coverage-on-rodman-renshaw-rating-set-to-buy", "source_name": "GuruFocus", "published_at": "2026-07-07T18:11:32", "published_display": "07 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Atossa Genetics stock with buy rating By Investing.com", "summary": "Rodman & Renshaw has initiated coverage on Atossa Genetics Inc. (NASDAQ:ATOS) with a buy rating and a $12.00 price target. The firm highlighted Atossa's estrogen receptor modulator, which shows clinical activity in breast cancer treatment and has validated clinical results, along", "url": "https://za.investing.com/news/stock-market-news/rodman--renshaw-initiates-atossa-genetics-stock-with-buy-rating-93CH-4358519", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T14:11:32", "published_display": "07 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rodman & Renshaw initiates Atossa Genetics stock with buy rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPNl9UaVFKUEpWLXhkVS1pVmdpdVdYWVhPVnY2WGVKN181Y2V1dkRPNTBfekZDUWNvMlpCOV9QaHQ2N3JDYnBLbldqS1BKVUJPTUVpeXlaMHNpb2V5MktReXlNdjZxM3l6UXA0SXhEb09Gb1JhZlE3MnpsWklTSjU3dExZNHJhcEE3WWRQNkZBX3dOSEJjRGxXU211aVpWWGE5RHYySW51UEpzVndpcFZWQ0lEY3dYTzVvbmh1Y01uUWo?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T12:38:29+00:00", "published_display": "07 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ATOS - Atossa Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Atossa Therapeutics Inc.'s (ATOS) financial data and stock performance, with a specific focus on its short interest. Key metrics include market capitalization, price-to-book ratio, EPS growth, insider and institutional ownership, and v", "url": "https://finviz.com/stock?t=ATOS&ta=1&p=m&ty=si&b=2", "source_name": "Finviz", "published_at": "2026-07-07T00:11:32", "published_display": "07 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Benchmark Index", "summary": "Atossa Therapeutics, Inc. (NasdaqCM:ATOS) has been added to the Russell Microcap Value Benchmark Index. This inclusion follows its recent addition to the Russell 3000E Index, the Russell Microcap Index, and the Russell 3000E Growth Benchmark. The company is a clinical-stage bioph", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f326", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:16", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell Microcap Index", "summary": "Atossa Therapeutics, Inc. (NasdaqCM: ATOS) has been added to the Russell Microcap Index, as announced on June 29, 2026. This inclusion is significant for the clinical-stage biopharmaceutical company, which focuses on developing treatments for women\u2019s breast cancer and other breas", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-microcap-index-ce7f5fdeda81f02d", "source_name": "marketscreener.com", "published_at": "2026-06-29T09:09:57", "published_display": "29 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atossa Therapeutics, Inc. \u2013 NASDAQ:ATOS", "summary": "This article provides financial information for Atossa Therapeutics, Inc. (NASDAQ: ATOS), specifically its \"Price to book forward\" metric. The content emphasizes that the market was closed at the time of publication, and no trades were made. It also lists various data sources and", "url": "https://www.tradingview.com/symbols/NASDAQ-ATOS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:11:33", "published_display": "29 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc.(NasdaqCM: ATOS) added to Russell 3000E Growth Benchmark", "summary": "Atossa Therapeutics, Inc. (ATOS) has been included in the Russell 3000E Growth Benchmark. This addition highlights the clinical-stage biopharmaceutical company's progress in developing medicines for unmet medical needs in oncology, particularly focusing on breast cancer with its ", "url": "https://www.marketscreener.com/news/atossa-therapeutics-inc-nasdaqcm-atos-added-to-russell-3000e-growth-benchmark-ce7f5fdeda88f527", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:11:33", "published_display": "29 Jun 2026 04:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This page provides financial information for Atossa Therapeutics, Inc. (MUN:YAG), specifically focusing on its forward price-to-sales ratio. It indicates that the market for this stock was closed with no trades recorded at the time of viewing. The content appears to be a financia", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:09", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This article provides financial information for Atossa Therapeutics, Inc. (MUN:YAG) listed on the Munich Stock Exchange, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's financial data and is presented within the TradingView plat", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:11:33", "published_display": "26 Jun 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Atossa Therapeutics, Inc. \u2013 MUN:YAG", "summary": "This article displays the price to book forward metric for Atossa Therapeutics, Inc. (MUN:YAG) on the Munich Stock Exchange. It notes the market is currently closed with no trades. The information is presented within the TradingView platform context.", "url": "https://www.tradingview.com/symbols/MUN-YAG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:24", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics, Inc. (NASDAQ:ATOS): Are Analysts Optimistic?", "summary": "Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biopharmaceutical company, is expected by analysts to reach profitability in 2028, after incurring a loss of US$38m in the latest trailing-twelve-month period. This breakeven projection relies on a very high average annual growt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atos/atossa-therapeutics/news/atossa-therapeutics-inc-nasdaqatos-are-analysts-optimistic", "source_name": "Simply Wall Street", "published_at": "2026-06-25T10:39:59", "published_display": "25 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com", "summary": "Atossa Therapeutics has announced a registered direct offering to institutional investors, aiming to raise approximately $4.5 million in gross proceeds. The offering involves the sale of common stock and warrants, with potential for an additional $12 million if warrants are fully", "url": "https://ng.investing.com/news/stock-market-news/atossa-therapeutics-raises-45m-in-registered-direct-offering-93CH-2553830", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T16:11:01", "published_display": "19 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds", "summary": "Atossa Therapeutics announced the closing of a registered direct offering, generating approximately $4.5 million in gross proceeds upfront, with the potential for an additional $12 million from warrant exercises. The offering involved shares of common stock and Series A and Serie", "url": "https://www.biospace.com/press-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds", "source_name": "BioSpace", "published_at": "2026-06-14T13:48:50", "published_display": "14 Jun 2026 13:48", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics closes $4.5M registered direct offering By Investing.com", "summary": "Atossa Therapeutics recently completed a registered direct offering, securing $4.5 million in gross proceeds. This financing involved the sale of common stock and warrants, which could bring in an additional $12 million if fully exercised. The company plans to use these funds for", "url": "https://ng.investing.com/news/stock-market-news/atossa-therapeutics-closes-45m-registered-direct-offering-93CH-2556863", "source_name": "Investing.com Nigeria", "published_at": "2026-06-13T01:39:03", "published_display": "13 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-drug developer Atossa raises $4.5M, eyes $12M more", "summary": "Atossa Therapeutics has closed a registered direct offering, securing approximately $4.5 million in gross proceeds from the sale of common shares and warrants. The offering also provides the potential for an additional $12 million if all Series Warrants are fully exercised. The c", "url": "https://www.stocktitan.net/news/ATOS/atossa-therapeutics-announces-closing-of-registered-direct-offering-6motup1g63u1.html", "source_name": "Stock Titan", "published_at": "2026-06-13T01:09:57", "published_display": "13 Jun 2026 01:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics closes $4.5M registered direct offering", "summary": "Atossa Therapeutics, Inc. has successfully completed a registered direct offering, securing approximately $4.5 million in gross proceeds. The biopharmaceutical company sold common stock and warrants, which could bring in an additional $12 million if fully exercised. Atossa plans ", "url": "https://www.investing.com/news/company-news/atossa-therapeutics-closes-45m-registered-direct-offering-93CH-4740652", "source_name": "Investing.com", "published_at": "2026-06-12T22:09:57", "published_display": "12 Jun 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering", "summary": "Atossa Therapeutics has announced a registered direct offering with institutional investors, expected to generate $4.5 million upfront and potentially up to $16.5 million if warrants are fully exercised. The offering includes common stock and Series A and B warrants, with proceed", "url": "https://pulse2.com/atossa-therapeutics-announces-up-to-16-5-million-registered-direct-offering/", "source_name": "Pulse 2.0", "published_at": "2026-06-12T20:39:03", "published_display": "12 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal", "summary": "Atossa Therapeutics is conducting a registered direct offering to sell 1,363,637 shares of common stock, each combined with one Series A warrant and one Series B warrant, at an offering price of $3.30 per share, aiming for gross proceeds of $4,500,002.10 and estimated net proceed", "url": "https://www.stocktitan.net/sec-filings/ATOS/424b5-atossa-therapeutics-inc-prospectus-supplement-debt-securities-27b92621b700.html", "source_name": "Stock Titan", "published_at": "2026-06-12T13:09:57", "published_display": "12 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Launches $16.5 Million Registered Direct Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atossa-therapeutics-launches-16-5-123940376.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:39:40+00:00", "published_display": "11 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics stock tumbles on $4.5M stock offering", "summary": "Atossa Therapeutics Inc. (NASDAQ: ATOS) shares fell 30% in premarket trading after announcing a registered direct offering expected to raise $4.5 million. The company entered into an agreement with institutional investors to sell 1,363,638 shares of common stock at $0.18 par valu", "url": "https://www.investing.com/news/stock-market-news/atossa-therapeutics-stock-tumbles-on-45m-stock-offering-93CH-4737416", "source_name": "Investing.com", "published_at": "2026-06-11T13:09:31", "published_display": "11 Jun 2026 13:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics raises $4.5M in registered direct offering", "summary": "Atossa Therapeutics, Inc. announced a registered direct offering raising approximately $4.5 million in gross proceeds. The clinical-stage biopharmaceutical company is selling over 1.3 million shares and accompanying warrants, with potential for an additional $12 million if warran", "url": "https://www.investing.com/news/company-news/atossa-therapeutics-raises-45m-in-registered-direct-offering-93CH-4737315", "source_name": "Investing.com", "published_at": "2026-06-11T12:40:21", "published_display": "11 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRjNZMk51a1lKYjRHV1AycHdqR1I1SzdpeHpPckJxZWhSR1JvLXd6dWh6bjkwVHVRdUpCUE9qVzNwLXlaTFpVXy1UUHFMdTNiTkRXTlFLYkx3U1ZnTEdZejQyejNVY0hBb2Z1MThQX29XcUR6R25IajJNeFpXT0M5QUo3RnU3MlBsSFBGOUZlc19DaFQydGpVb2ZXMXpXTE1Zb2pIMFJzbnREcGtPNXVzM2R4eDcwNU96MTg1Q0hsb3BCQWpkZFQ1NzF4bzVMb0ZYUWh6R3FFeHFya0VzUDNjMkRiVWc2cjQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOd0gzU20xb1JicDl1OVV0dGY4VlY0ekJjYWkwSWVmVUNIMFFfQ0RwYkQ1OE1VS1ExeDNRNWxXRDJZUi1KMHRIeF90d1ZrSG4zYVFmbC1faXJsRFRMUkt1OHFsVUlYSzMzdHM4TDF0OXdYdmZDVU0zb2E0QkRaUWx0V0dqbWdEZUU3VmhjUlVjeVZzd0ZzTE9zbmw3UFItdng0Ul9leEp1STB4MVpPVDN3R2RB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment", "summary": "", "url": "https://finance.yahoo.com/video/atossa-therapeutics-highlights-endoxifen-progress-165144742.html", "source_name": "Proactive", "published_at": "2026-06-10T16:51:44+00:00", "published_display": "10 Jun 2026 16:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ceo-chat-steven-quay-md-090500232.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-01T09:05:00+00:00", "published_display": "01 Jun 2026 09:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxQbVFCZnVDcGQ4b2lmMVhKY2RTWUl6YjVDdjh2V3hiVE55UUkyNGVrUGRSNFZJbjdHSXdvSXRESG9BQ0o4LUVDX0FrQV9EUGJ2UWRXa0lGNGNsMXpzMlV6bnhsVHJlU1RMT0hSQ1V6elVzQ2p5VUQtdE91bmhFYVhlSzIybzRHUGVHNVVwMU56TlRaLUVtRk9wT2ZfY3VWc2ZXc2hVcFl5c0RIc1E0Wm0xUUtTMVJRamJXZWJZeU1CTFRtNjJKNElyb2FwQmEyQUhJRklVZU9jNEFodXYzRFhvdlNZUkhwdDliWTFpQmVScW01elhfRWo5VWpYaGU2WUJ6SWRsMWtUbzg0VmxqanVFVldVTWFIaV9WczZqRHpvYk5VZ0RD?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOQk9CNTZXSUw3V0VKUXFIcFlNblJKM3ROdGpHY0RYWmVrX0gtaGo5SS1YcnpxX1JnS2poU2JLTGc4TENHaTQ1S3hiUnQyVGRIVHJ2OVh3TGxobEpqSkR3S2RCRTU4YnhzZFMzcHNaam80Ymo4LXFGVTNaejl6ZlA0U0tDck1FaWppRVNHQ19DWFl0U3FUWkwxYWFVOTd1LWRObUNKWXRsQ3lxcnV5OXZBNU96eHBoRXRjUDhYMzAyODdmSnlPRE9kYnFDeFR6Zng4V2ZZb0lndHduRXJlaWp4OE5pc190VXdRZi1YRlJVQXIteUVydTd3akNrVUUzcW1ldWR3ZTRBUDZzV3hCRmljUE1WZmRrQ1NMRFRicmlCeVNrY2swX0E?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/atossa-therapeutics-host-virtual-kol-123000263.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics (NASDAQ: ATOS) wins OK for potential reverse stock split", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQQm1VamtBcGhab0R6NElKWlE3Um0wRUdRbXZoMl9tWEVZYTlseExmX2NoWjd2Q2E1ZUtmYVBJdzhjeHhZNC11OHlFMlZPdW9OQ25fMGhhaThyVUpBekE2ZmdsT2NpQXJvM1JsbkFTSmhBYWtOSWdZeVB3ckhVWmRsQkdOcGdoQ1M1SkItMm5nR09YTktLYUxpdXFIal9JSm9zUWh6WTRlUzdqdC1xRlU1dHp3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics stock surges after FDA rare disease designation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOHYwdnhzam52OXkwc0JZZGtKY1BtU0JoTEFTelNOM3VtMFNSUmxaNk5LaEE5VnBHSEl1LURUamQzc19fRWNSaUF1a3RhakhWd3liT3JFVEE5WWV1cE1HSThZWXBKZWNvSlo4T0doM1Z3S2JndVg3N0NJRjNSc19TUlJwS0hhdDZxV0pPRExGa2xGNTlSV0Y2LTZ0dTNUWHo0cVV5UjM3dGtZV0kySHg2cmQ3andSMWtuZl9qOXh0dGxwTE0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Therapeutics reaches settlement in Endoxifen patent dispute", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPVXZDbFVGajdmN2x6N0xlVGh1UUlxb0VDenFVNUkwR3JnaW9tOEl4NjdtZ2I1anlZVlZVLS1GRnB6eTJNWnh5b2stSHBIMXNoSUllcjlUVVM0SnNkSjVkV1hUUzJpSXNXaG9wOW5MM05Wckttanpla0xUWUJJUkNhM0hlbWZVZnJ3ZnVPVGtMUG1DUHZZSDRPM1lIQWsxaF9VVUFEakFjdWpLQ21hZXpDQWtEMmlpTE9KWmZpVkdudw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQTV8tclhnZ2RvcEdVN1dmM0JoN2w4R19UMHNJeWkteDlMenJXNzE2XzJreVpWa1l4Z2xjQ01RU2NiUmtZanRWSUZ2bGd1RDNFalVoQmFsaGhKankyQUZSRTZCVE9CRk5PM0tkbUotQm83UDBweW5iajF5QzA0TGduME5MVWpDcHhOQW5F?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE9LTGNSLWZFVmhkVzBubkZQZE0tUWotTU9LWVFDdVJwSmMyeUd6MU5PV2ZCNF9YTElpS09yVGVLWEtQN0ZiZ2U3VThyWENXUFV2UEpKOU0xNXFVSHJHVFhBSlhqZGJnaHla?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:04:39+00:00", "published_display": "09 Jul 2025 17:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) Stock Forecast and Price Target 2026 $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFA5QUNLN0w1Ri16UTFCeHUyOVRaemRRVjBtcm9lUDgzcTF3ZjhhMm9BYjlkRGRna281UXRlTFBydEhPZngwQjVMSENtTmwxVVVManRSMDVwdDFHdnA0UkpoRGxzWmpwZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T16:27:16+00:00", "published_display": "11 May 2024 16:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Atossa Genetics (ATOS) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNUFFCcXNDcnJjc0J1VGU1aVcwV2VrQ1Nrdm1iR1NLSGNCZ09iQ09VTjVObU9MMWFuSWFOZUtXUjdqT3ZSbHVIYlF3RWhNWW5Jc2l2N2tfUW42MnZHZnB1cGFoSnZmSjd1bE5ySU1zTEpGVTlKb294WEgtZzRYZVFEWA?oc=5", "source_name": "MarketBeat", "published_at": "2020-04-29T04:32:22+00:00", "published_display": "29 Apr 2020 04:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics (ATOS) Stock Price, News & Analysis $ATOS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBBQVJfZDJSZENtXzJYVG82c1JRbXl6UlJDLUhfNzY1UXQtUFJQNGZyelU5M0JNSlBGRjF4RF85aTlGdXFiY0k4eEVVbGxHNzJ3RFk4dExnMDJvZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-21T18:04:37+00:00", "published_display": "21 Aug 2016 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atossa Genetics Announces FDA Acceptance of Its", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQUHRDZ1FHaWkzcVBCdTlXczd6SWRlLTBsM09WLVljQzNXakk3T3Boa1BPMTY5LUZQVDg0Z0I3UnB3OFNudy03UllScG5oRTZ4blVoajZSWW1HZ2ZOenNLSjBxTXBrWTVWRjJPdWRLZGdiU0ZSMnFKekpDUUxlTmtCaXdpQ2xGYTcySWNnaWZIVmlIVHUzcktfcWl6Tmo1Y3hQNlI2SDRiZnNkOXU0V1pEcXg2N2V3UDVEZm4xa3hGbGR4NHdMT2p4Q2pTU1RyakQ5UC1WMS1jeVREQ1plcEhsVktIQWVXa0VkRjN2S2lvTmlOLWx2MUg3RTA3eGhEaDNmT0lMcTQ0RUNRTDJNVTJGSW5xOFktQkRFaVhEZVRqR3h4M2E2c3pNb0NMbTliSHdHVWZPeDNrTjIyV3MwU014YVU0cFZWRTJHaE0zUGZwVWthZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2015-09-21T07:00:00+00:00", "published_display": "21 Sep 2015 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer tests: an interview with Dr Steven Quay, CEO of Atossa Genetics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZlNfR3J0aklRUWRWTUV6MjdJTU0wRTVJZlZUSTAxSVYxczNqQU9hU0c5UXBZS0NlWVJCdWNDY2ZWbTJHTjN6cGMxNnJLNVBhLWxha3VIcmYyeEdqOTZOQllXRTdMUHJ5OW5nQk1DYWxKV3FLSFRtV01lSk54ZG1nb2Q0VkVQMUtkOWZoOVVMTnhWODc5SXRFenZwWWFqczNrN2tMMVg1NFh6dGdEeXo3WTZGTTU4QVFEdGdiaXdJV0Q?oc=5", "source_name": "News-Medical", "published_at": "2013-02-22T08:00:00+00:00", "published_display": "22 Feb 2013 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 52, "sentiment_summary": {"positive": 14, "negative": 4, "neutral": 34, "score": 54, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.37, "latest_week": "2026-07-10", "one_week_move": 11.8, "four_week_move": -3.7, "twelve_week_move": -59.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.567865, "market_dynamics_buy_signal": false, "relative_strength": -76.988832, "fair_value_gap": -82.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.5332, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.8% over one week, -3.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "Investing.com", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "MarketBeat", "count": 4}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+11.8% over one week, -3.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates"}], "updated_at": "2026-07-16T05:28:42.230412+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}